PapersFlow Research Brief

Health Sciences · Medicine

Biological and pharmacological studies of plants
Research Guide

What is Biological and pharmacological studies of plants?

Biological and pharmacological studies of plants is the research field that characterizes plant-derived materials (extracts and isolated compounds) for their bioactive constituents, mechanisms of action, therapeutic effects, safety, and clinical relevance in humans and model systems.

The literature cluster labeled “Biological and pharmacological studies of plants” contains 294,039 works focused on traditional uses, pharmacological activities, and therapeutic potential of medicinal plants, including studies of bioactive compounds and their mechanisms. "Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics" (2016) exemplifies pharmacological synthesis work that integrates activity, toxicity, and pharmacokinetics for a specific plant-derived compound used in Chinese herbal medicine. Clinical and translational relevance—including efficacy uncertainty and herb–drug interactions—is illustrated by "Aloe vera: a systematic review of its clinical effectiveness." (1999) and "Acute heart transplant rejection due to Saint John's wort" (2000).

Topic Hierarchy

100%
graph TD D["Health Sciences"] F["Medicine"] S["Pharmacology"] T["Biological and pharmacological studies of plants"] D --> F F --> S S --> T style T fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan
294.0K
Papers
N/A
5yr Growth
120.3K
Total Citations

Research Sub-Topics

Why It Matters

Plant-based pharmacology directly affects patient safety, drug development, and evidence-based use of herbal products. A concrete high-stakes example is the clinical report "Acute heart transplant rejection due to Saint John's wort" (2000), which documents acute transplant rejection associated with a commonly used herbal product, underscoring that “natural” products can have clinically significant interactions in transplant medicine. Evidence appraisal also matters for everyday therapeutic claims: "Aloe vera: a systematic review of its clinical effectiveness." (1999) concluded that, despite some promising results, the clinical effectiveness of oral or topical aloe vera was not sufficiently defined at the time, illustrating why systematic evaluation is required before routine clinical recommendation. Mechanistic pharmacology of plant constituents can point to actionable targets in neuropsychopharmacology; for example, "Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo‐oligomeric GABA receptor from <i>Drosophila melanogaster</i>" (2003) links a dietary/medicinal monoterpenoid to GABAergic receptor modulation, providing a plausible basis for CNS-relevant effects that can be followed up with dosing, safety, and formulation studies. Cardiovascular herbal use is also a real clinical domain: "Cardiovascular effects of Danshen" (2007) focuses on cardiovascular pharmacology of a widely used traditional medicine, aligning botanical research with cardiology-relevant endpoints.

Reading Guide

Where to Start

Start with "Aloe vera: a systematic review of its clinical effectiveness." (1999) because it models how to evaluate plant-based interventions using clinical evidence synthesis and clearly states the limits of what was established.

Key Papers Explained

For mechanistic foundations, "Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo‐oligomeric GABA receptor from <i>Drosophila melanogaster</i>" (2003) provides a direct target-level example of how a plant constituent can modulate a defined receptor system. For constituent-to-therapeutic hypothesis mapping in neuropsychopharmacology, "Hyperforin as a possible antidepressant component of hypericum extracts" (1998) illustrates how an extract can be linked to a candidate active principle. For clinical risk and pharmacovigilance, "Acute heart transplant rejection due to Saint John's wort" (2000) shows that herb exposure can coincide with severe outcomes, motivating interaction screening and cautious co-administration. For integrative compound-level evaluation across efficacy and safety domains, "Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics" (2016) exemplifies how a single phytochemical can be assessed across pharmacology, toxicity, and pharmacokinetic behavior. For a disease-area application in cardiology, "Cardiovascular effects of Danshen" (2007) situates botanical pharmacology within cardiovascular endpoints and clinical interest.

Paper Timeline

100%
graph LR P0["3H-baclofen and 3H-GABA bind to ...
1981 · 1.0K cites"] P1["Importance of a novel GABAA rece...
1989 · 1.3K cites"] P2["Acute heart transplant rejection...
2000 · 650 cites"] P3["Thymol, a constituent of thyme e...
2003 · 488 cites"] P4["Historical Perspective of Tradit...
2014 · 561 cites"] P5["Emodin: A Review of its Pharmaco...
2016 · 731 cites"] P6["How deep learning extracts and l...
2017 · 555 cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P1 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Advanced work, as motivated by the above papers, centers on (i) standardizing extracts and linking chemotypes to reproducible pharmacology, (ii) formal herb–drug interaction assessment in high-risk settings modeled by "Acute heart transplant rejection due to Saint John's wort" (2000), and (iii) mechanistic deconvolution of multi-compound products into target-resolved pharmacology as exemplified by thymol’s receptor modulation in "Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo‐oligomeric GABA receptor from <i>Drosophila melanogaster</i>" (2003) and compound-centered synthesis in "Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics" (2016).

Papers at a Glance

In the News

Code & Tools

Recent Preprints

Latest Developments

Recent developments in the biological and pharmacological studies of plants include the discovery of genes involved in the biosynthesis of important compounds like Taxol (baccatin III) transferred into tobacco plants, which could lower production costs for cancer drugs (Nature, June 2025), advancements in understanding plant metabolic pathways such as salicylic acid biosynthesis (Nature, July 2025), and the identification of plant genes that could reduce the cost of producing key pharmaceuticals like Taxol (Science, July 2025). Additionally, conferences in 2026 are focusing on innovative plant biotechnology, crop resilience, and sustainable agriculture, reflecting ongoing research trends (Plant and Molecular Conference 2026, Plant Biology 2026, Plant Biology Conference in Prague).

Frequently Asked Questions

What do biological and pharmacological studies of plants typically measure?

They typically measure bioactivity (e.g., receptor modulation), therapeutic effects in relevant models, and safety-related properties such as toxicity and pharmacokinetics. "Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics" (2016) explicitly frames plant-compound evaluation around pharmacology, toxicity, and pharmacokinetics as a linked evidence package.

How are mechanisms of action established for plant-derived compounds?

Mechanisms are established by connecting defined molecules to molecular targets using pharmacological assays and receptor-level experiments. "Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo‐oligomeric GABA receptor from <i>Drosophila melanogaster</i>" (2003) demonstrated target-level modulation of GABA receptors by thymol, providing a mechanistic anchor for subsequent translational work.

Why can herbal products cause serious drug interactions in clinical care?

Herbal products can alter clinically critical pharmacology when co-administered with conventional drugs, leading to loss of efficacy or toxicity. "Acute heart transplant rejection due to Saint John's wort" (2000) reported acute rejection in a transplant context, showing that herb exposure can coincide with catastrophic clinical outcomes and therefore requires active medication reconciliation and monitoring.

Which kinds of evidence help determine whether a medicinal plant is clinically effective?

Systematic reviews of clinical studies help determine whether benefits are supported by sufficiently consistent and rigorous human evidence. "Aloe vera: a systematic review of its clinical effectiveness." (1999) concluded that clinical effectiveness of oral or topical aloe vera was not sufficiently defined, illustrating how evidence synthesis can temper or refine therapeutic claims.

Which papers connect plant constituents to neuropsychiatric pharmacology?

"Hyperforin as a possible antidepressant component of hypericum extracts" (1998) links a specific constituent to antidepressant-relevant effects within Hypericum extracts, and "Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo‐oligomeric GABA receptor from <i>Drosophila melanogaster</i>" (2003) connects a plant monoterpenoid to GABAergic receptor modulation. Together, these examples show how botanical mixtures can be decomposed into candidate active principles and then mapped onto defined CNS targets.

How do traditional medical practices influence modern pharmacological research on plants?

Traditional practices guide candidate selection, usage patterns, and hypotheses about therapeutic indications, but they still require pharmacological and clinical validation. "Historical Perspective of Traditional Indigenous Medical Practices: The Current Renaissance and Conservation of Herbal Resources" (2014) discusses the modern resurgence of herbal medicines and the conservation context that shapes how traditional knowledge is translated into research priorities.

Open Research Questions

  • ? Which specific molecular targets and downstream pathways best explain the reported antidepressant-relevant activity attributed to hyperforin in "Hyperforin as a possible antidepressant component of hypericum extracts" (1998), and how do these mechanisms translate across extract compositions?
  • ? Which pharmacokinetic and toxicity determinants most strongly constrain clinical translation of emodin as summarized in "Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics" (2016), and what exposure ranges are compatible with therapeutic effects without unacceptable risk?
  • ? Which patient populations and co-medications are at highest risk for severe adverse outcomes similar to those described in "Acute heart transplant rejection due to Saint John's wort" (2000), and what monitoring strategies prevent recurrence?
  • ? Which receptor subtypes and binding-site features govern plant-derived modulation of GABAergic signaling as shown in "Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo‐oligomeric GABA receptor from <i>Drosophila melanogaster</i>" (2003), and how does this vary by chemotype and formulation?
  • ? Which cardiovascular endpoints and mechanisms should be prioritized to evaluate herbal cardiovascular agents discussed in "Cardiovascular effects of Danshen" (2007) in ways that are comparable to conventional cardiology therapeutics?

Research Biological and pharmacological studies of plants with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Biological and pharmacological studies of plants with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers